{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:21:52Z","timestamp":1789924912717,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T00:00:00Z","timestamp":1698537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.amjcard.2023.10.073","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T15:29:24Z","timestamp":1706542164000},"page":"S77-S82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S","title":["Advances in the Management of Hypertrophic Cardiomyopathy Leading to Low Disease-Related Mortality in 2023"],"prefix":"10.1016","volume":"212","author":[{"given":"Barry J.","family":"Maron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan J.","family":"Rowin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2023.10.073_bib0001","doi-asserted-by":"crossref","unstructured":"Braunwald E, Lambrew E, Rockoff D, Rockoff D, Ross J Jr., Morrow AG. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. Circulation 1964;29:IV-3\u2013IV-119.","DOI":"10.1161\/01.CIR.29.5S4.IV-3"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021095","article-title":"Cardiovascular diseases that have emerged from the darkness","volume":"10","author":"Maron","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0003","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamacardio.2015.0354","article-title":"How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice","volume":"1","author":"Maron","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0004","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.amjcard.2022.06.007","article-title":"Ventricular septal myectomy for obstructive hypertrophic cardiomyopathy (analysis spanning 60 years of practice): AJC Expert Panel","volume":"180","author":"Maron","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0005","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC State-of-the-Art Review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0006","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0007","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.298.4.405","article-title":"Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy","volume":"298","author":"Maron","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0008","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.amjmed.2020.03.015","article-title":"Hypertrophic cardiomyopathy: is a \u201ccure\u201d coming\u2026or is it already here?","volume":"133","author":"Maron","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0009","unstructured":"Maron MS, Rowin EJ, Maron BJ.The paradigm of sudden death prevention in hypertrophic cardiomyopathy. Am J Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJM200002103420601","article-title":"Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy","volume":"342","author":"Maron","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0011","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jacep.2022.07.012","article-title":"Temporal and global trends of the incidence of sudden cardiac death in hypertrophic cardiomyopathy","volume":"8","author":"Abdelfattah","year":"2022","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0012","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2023.04.056","article-title":"Development of the implantable cardioverter-defibrillator: JACC Historical Breakthroughs in Perspective","volume":"82","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0013","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.hrthm.2021.01.019","article-title":"Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: twenty years with the implantable cardioverter-defibrillator","volume":"18","author":"Maron","year":"2021","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.005820","article-title":"Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators","volume":"11","author":"Maron","year":"2018","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/jamacardio.2019.1391","article-title":"Enhanced American College of Cardiology\/American Heart Association strategy for pre-vention of sudden cardiac death in high-risk patients with hyper-trophic cardiomyopathy","volume":"4","author":"Maron","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0016","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2016.11.063","article-title":"Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management","volume":"69","author":"Rowin","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0017","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0018","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.jacc.2016.05.002","article-title":"The father of septal myectomy for obstructive HCM, who also had HCM: the unbelievable story","volume":"67","author":"Maron","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0019","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","article-title":"Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction","volume":"66","author":"Maron","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.amjcard.2021.09.040","article-title":"Outcomes over follow-up \u226510 years after surgical myectomy for symptomatic obstructive hypertrophic cardiomyopathy","volume":"163","author":"Maron","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0021","article-title":"Lifetime clinical course of hypertrophic cardiomyopathy: outcome of the historical Florence cohort over 5 decades","volume":"2","author":"Maurizi","year":"2023","journal-title":"JACC Adv"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0022","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/CIRCHEARTFAILURE.109.922872","article-title":"Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy","volume":"3","author":"Maron","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0023","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.amjcard.2017.12.044","article-title":"Impact of advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy","volume":"121","author":"Rowin","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0024","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jacc.2017.06.011","article-title":"Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a word of balance","volume":"70","author":"Sorajja","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0025","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1016\/j.jacc.2020.08.044","article-title":"2020 AHA\/ACC guidelines for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0026","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomized, double-blind, placebo-controlled phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0027","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/CIRCULATIONAHA.120.051330","article-title":"Exploring new and old therapies for obstructive hypertrophic cardiomyopathy: mavacamten in perspective","volume":"143","author":"Maron","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0028","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024566","article-title":"Future role of new negative inotropic agents in the era of established surgical myectomy for symptomatic obstructive hypertrophic cardiomyopathy","volume":"11","author":"Maron","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0029","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of Aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0030","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0031","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.123.065037","article-title":"Evolving contemporary management of atrial fibrillation in hypertrophic cardiomyopathy","author":"Rowin","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0032","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0033","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1161\/CIRCULATIONAHA.117.027738","article-title":"Perspectives on the overall risks of living with hypertrophic cardiomyopathy","volume":"135","author":"Maron","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0034","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jacc.2020.04.045","article-title":"Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction","volume":"75","author":"Rowin","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0035","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jchf.2018.03.004","article-title":"Global burden of hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0036","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.amjcard.2015.04.027","article-title":"Importance and feasibility of creating hypertrophic cardiomyopathy centers in developing countries: the experience in India","volume":"116","author":"Maron","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0037","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1093\/eurheartj\/ehu280","article-title":"Hypertrophic cardiomyopathy in the developing world: focus on India","volume":"35","author":"Maron","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0038","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.amjcard.2022.07.033","article-title":"Personalized treatment strategies effective in hypertrophic cardiomyopathy do not rely on genomics in 2022: a different tale of precision medicine","volume":"183","author":"Maron","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2023.10.073_bib0039","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.amjcard.2017.08.048","article-title":"Interaction of adverse disease related pathways in hypertrophic cardiomyopathy","volume":"120","author":"Rowin","year":"2017","journal-title":"Am J Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923012535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923012535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:52:00Z","timestamp":1757573520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914923012535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":39,"alternative-id":["S0002914923012535"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.10.073","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the Management of Hypertrophic Cardiomyopathy Leading to Low Disease-Related Mortality in 2023","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.10.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}